Overview

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Status:
RECRUITING

Trial end date:
2027-05-06

Target enrollment:

Participant gender:

Summary

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).

Phase:

PHASE3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Docetaxel
Irinotecan
Paclitaxel
trifluridine tipiracil drug combination